Repligen corp stock.
The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...
Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Company Info. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of …While Repligen Corporation (NASDAQ:RGEN) might not be the most widely known stock at the moment, it received a lot of attention from a substantial price increase on the NASDAQGS over the last few ...Nov 30, 2023 · The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Repligen Corp. shares valued at $557,328 were sold by Gebski Christine on Nov 10. At $147.13 per share, Gebski Christine sold 3,788 shares.
Waltham, Massachusetts 02453. Phone 1 781 250-0111. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue $801.54M. Net Income $185.96M. 2022 Sales Growth 19.54%.4.08%. $2.65B. CureVac N.V. 1.85%. $1.21B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing ...Mar 27, 2023 · During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $157.11. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 36.92%.
Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.752 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare Steris PLC and Repligen Corp Stock ...Repligen Corp. SEC filings breakout by MarketWatch. View the RGEN U.S. Securities and Exchange Commission reporting information.4 thg 4, 2016 ... Once you've won approval for a biologic, or biosimilar, manufactured at a particular facility, you can't just switch to another without jumping ...As of February 22, 2023, Repligen Corp had a $9.9 billion market capitalization, compared to the Medical Equipment, Supplies & Distribution median of $330.1 million. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 5.92% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.8.
Repligen Corp’s Stock Price as of Market Close. As of April 28, 2023, 4:00 PM CST, Repligen Corp’s stock price was $151.63. Repligen Corp is up 4.46% from its previous closing price of $145.15. During the last market session, Repligen Corp’s stock traded between $144.20 and $149.36.
Total revenue as reported for the full year 2022 increased to $801.5 million compared to $670.5 million for the full year 2021, a year-over-year gain of 20%, or 25% at constant currency, overall ...
On average, Wall Street analysts predict that Repligen's share price could reach $188.75 by Nov 2, 2024. The average Repligen stock price prediction forecasts a ...Find the latest Repligen Corp (RGN.SG) stock quote, history, news and other vital information to help you with your stock trading and investing.On September 12, 2023, Repligen Corp (HONE) stock performed well, with a median target price forecast of $200.00. The consensus among the 13 polled investment analysts is to buy stock in Repligen Corp. Repligen Corp is expected to release its current quarter earnings report on October 26. The company is projected to have earnings per share of ...Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.Get the LIVE share price of Repligen Corp(RGEN) and stock performance in one place to strengthen your trading strategy in US stocks. Now Start Investing in Repligen Corp on Groww. Repligen Corp. Healthcare. $159.49 +2.59(1.65%) 1D. 1D. 1W. 1M. 1Y. 3Y. 5Y. Performance. Open Price: Prev. Close: Volume: Avg. Volume: $157.90: $156.90: 553,227:RGEN Repligen Corp. 161.78 1.57 ( 0.98%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats.Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.
Oct 3, 2023 · Repligen Corp stock has a Value Score of 5, Momentum Score of 54 and Estimate Revisions Score of 37. Comparing Agiliti Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen …Find the latest Repligen Corp (RGN.BE) stock quote, history, news and other vital information to help you with your stock trading and investing.Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 38 and Quality Score of 71. Comparing Abbott Laboratories and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Get Repligen Corp (RGEN.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments11 brokers have issued 12-month price targets for Repligen's stock. Their RGEN share price targets range from $165.00 to $210.00. On average, they expect the company's …
Oct 13, 2023 · The Growth Grade Winner: Repligen Corp. As you can clearly see from the Growth Grade breakdown above, Repligen Corp has a more attractive growth grade than Medtronic PLC. For investors who focus solely on how a company is growing relative to other companies in the same industry, Repligen Corp could be a good stock to add to their portfolio.
Sep 18, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.On October 17, 2023, Repligen Corp (RGEN) stock showed promising performances, with a median target price forecast of $195.00 by 13 analysts. This represents a potential increase of 33.96% from the last recorded price of $145.57. The high estimate for the stock price is $240.00, while the low estimate is $165.00.Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. The number of shares of the Company's common stock, $0.01 par value per share ("Common Stock"), entitled to vote at the Annual Meeting was 55,429,107. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 51,525,212, representing 92.96% of the total number of shares of Common Stock entitled to vote ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.
Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.
Nov 30, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.
Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 63.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp (NASDAQ:RGEN) 157.02 Delayed Data As of Nov 21 +1.38 / +0.89% Today’s Change 110.45 Today ||| 52-Week Range 200.98 -7.26% Year-to-Date Quote …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 48.1. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%.Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.Repligen Corp (RGEN) will release its next earnings report on Feb 15, 2024. In the last quarter Repligen Corp reported $0.165 EPS in relation to $0.23 expected by the market. ... Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the ...UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of …View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.While Repligen Corporation (NASDAQ:RGEN) might not be the most widely known stock at the moment, it received a lot of attention from a substantial price increase on the NASDAQGS over the last few ...Repligen Company Info. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs.
Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise. Get the latest Repligen Corporation …Repligen Corp’s ( RGEN) price is currently up 0.21% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $171.57. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.02%.View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.Repligen Corp’s ( RGEN) price is currently down 4.66% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $160.14. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 37.23%.Instagram:https://instagram. rail stocksspacex stock valuebest forex trading accountwhat are junk bonds Dec 2, 2023 · Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis. Repligen - RGEN - Stock Price Today - Zacks Repligen (RGEN) (Delayed Data from NSDQ) $164.94 USD +7.69 (4.89%) Updated Dec 1, 2023 04:00 PM ET After-Market: $161.40 -3.54 (-2.15%) 7:58 PM ET... ita holdingshow do you invest in oil futures Repligen has a market cap of $14.2 billion, while Catalent is valued at $20.2 billion. RGEN shares are down year-to-date through Wednesday, while CTLT has dropped 12%. health insurance companies for young adults Stock analysis for Repligen Corp (RGEN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.RGEN | AI Stock Analysis for Repligen Corp. RGEN Including Stock Price, Stock Chart, Technical, Fundamental, Sentiment Analysis and More.